{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:41:05Z","timestamp":1777948865974,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,3]]},"DOI":"10.7759\/cureus.108189","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T21:01:41Z","timestamp":1777842101000},"source":"Crossref","is-referenced-by-count":0,"title":["Bentracimab for Surgical and Perioperative Bleeding: Clinical Efficacy, Emerging Safety Concerns, and Implementation Challenges (Cost, Accessibility, and Evidence Gaps)"],"prefix":"10.7759","author":[{"given":"Anisha","family":"Bai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waseem","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiq","family":"Baig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Mudasir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashir","family":"Kanwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haroon","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria L","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2019.06.028","article-title":"Hemostasis management of patients undergoing emergency cardiac surgery after ticagrelor loading","volume":"34","author":"Williams B","year":"2020","unstructured":"Williams B, Henderson RA, Reformato VS, Pham T, Taylor BS, Tanaka KA. Hemostasis management of patients undergoing emergency cardiac surgery after ticagrelor loading. J Cardiothorac Vasc Anesth. 2020, 34:168-74. 10.1053\/j.jvca.2019.06.028","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/14017431.2016.1231935","article-title":"Platelet inhibition and bleeding complications in cardiac surgery: a review","volume":"50","author":"Hansson EC","year":"2016","unstructured":"Hansson EC, Jeppsson A. Platelet inhibition and bleeding complications in cardiac surgery: a review. Scand Cardiovasc J. 2016, 50:349-54. 10.1080\/14017431.2016.1231935","journal-title":"Scand Cardiovasc J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901778","article-title":"Antibody-based ticagrelor reversal agent in healthy volunteers","volume":"380","author":"Bhatt DL","year":"2019","unstructured":"Bhatt DL, Pollack CV, Weitz JI, et al.. Antibody-based ticagrelor reversal agent in healthy volunteers. N Engl J Med. 2019, 380:1825-33. 10.1056\/NEJMoa1901778","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.117.006132","article-title":"Frequency, reasons, and impact of premature ticagrelor discontinuation in patients undergoing coronary revascularization in routine clinical practice: results from the Bern Percutaneous Coronary Intervention Registry","volume":"11","author":"Zanchin T","year":"2018","unstructured":"Zanchin T, Temperli F, Karagiannis A, et al.. Frequency, reasons, and impact of premature ticagrelor discontinuation in patients undergoing coronary revascularization in routine clinical practice: results from the Bern Percutaneous Coronary Intervention Registry. Circ Cardiovasc Interv. 2018, 11:e006132. 10.1161\/CIRCINTERVENTIONS.117.006132","journal-title":"Circ Cardiovasc Interv"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12734","article-title":"Population pharmacokinetic-pharmacodynamic modeling of PB2452, a monoclonal antibody fragment being developed as a ticagrelor reversal agent, in healthy volunteers","volume":"11","author":"Kathman SJ","year":"2022","unstructured":"Kathman SJ, Wheeler JJ, Bhatt DL, Arnold SE, Lee JS. Population pharmacokinetic-pharmacodynamic modeling of PB2452, a monoclonal antibody fragment being developed as a ticagrelor reversal agent, in healthy volunteers. CPT Pharmacometrics Syst Pharmacol. 2022, 11:68-81. 10.1002\/psp4.12734","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.117.005579","article-title":"Platelet transfusion for ticagrelor reversal","volume":"10","author":"Kruger P","year":"2017","unstructured":"Kruger P, Chan N, Eikelboom JW. Platelet transfusion for ticagrelor reversal. Circ Cardiovasc Interv. 2017, 10:10.1161\/CIRCINTERVENTIONS.117.005579","journal-title":"Circ Cardiovasc Interv"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000005148","article-title":"Platelet P2Y12 receptor inhibition and perioperative patient management","volume":"142","author":"Mazzeffi M","year":"2025","unstructured":"Mazzeffi M, Tanaka KA, Gurbel PA, Tantry US, Levy JH. Platelet P2Y12 receptor inhibition and perioperative patient management. Anesthesiology. 2025, 142:202-16. 10.1097\/ALN.0000000000005148","journal-title":"Anesthesiology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-023-01245-3","article-title":"Clinical and pre-clinical pharmacokinetics and pharmacodynamics of bentracimab","volume":"62","author":"Ortega-Paz L","year":"2023","unstructured":"Ortega-Paz L, Giordano S, Franchi F, Rollini F, Pollack CV Jr, Bhatt DL, Angiolillo DJ. Clinical and pre-clinical pharmacokinetics and pharmacodynamics of bentracimab. Clin Pharmacokinet. 2023, 62:673-92. 10.1007\/s40262-023-01245-3","journal-title":"Clin Pharmacokinet"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz748.0137","article-title":"Evaluation of the pharmacodynamics of a ticagrelor reversal agent PB2452","volume":"40","author":"Jennings L","year":"2019","unstructured":"Jennings L, Curry BJ, Bhatt DL, Pollack CV Jr, Weitz JI, Xu S, Lee JS. Evaluation of the pharmacodynamics of a ticagrelor reversal agent PB2452. Eur Heart J. 2019, 40:ehz748.0137.","journal-title":"Eur Heart J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-622928","article-title":"Structural and functional characterization of a specific antidote for ticagrelor","volume":"125","author":"Buchanan A","year":"2015","unstructured":"Buchanan A, Newton P, Pehrsson S, et al.. Structural and functional characterization of a specific antidote for ticagrelor. Blood. 2015, 125:3484-90. 10.1182\/blood-2015-01-622928","journal-title":"Blood"},{"key":"ref11","unstructured":"ClinicalTrials.gov. Study to evaluate the safety, tolerability, PK, and PD of PB2452 in healthy volunteers. (2024). Accessed. March 24, 2026: https:\/\/clinicaltrials.gov\/study\/NCT03492385."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13511","article-title":"Effects of autologous platelet transfusion on platelet inhibition in ticagrelor-treated and clopidogrel-treated subjects","volume":"14","author":"Teng R","year":"2016","unstructured":"Teng R, Carlson GF, Nylander S, Andersson TL. Effects of autologous platelet transfusion on platelet inhibition in ticagrelor-treated and clopidogrel-treated subjects. J Thromb Haemost. 2016, 14:2342-52. 10.1111\/jth.13511","journal-title":"J Thromb Haemost"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15219","article-title":"Reversal of the antiplatelet effect of ticagrelor by simulated platelet transfusion","volume":"59","author":"Zhang S","year":"2019","unstructured":"Zhang S, Xu K, Mei L, et al.. Reversal of the antiplatelet effect of ticagrelor by simulated platelet transfusion. Transfusion. 2019, 59:1850-6. 10.1111\/trf.15219","journal-title":"Transfusion"},{"key":"ref14","unstructured":"ClinicalTrials.gov. Study to evaluate the safety, tolerability, PK and PD of PB2452 in healthy younger, older and elderly subjects. (2024). Accessed. March 24, 2026: https:\/\/clinicaltrials.gov\/study\/NCT03928353."},{"key":"ref15","unstructured":"ClinicalTrials.gov. Phase 2B study to evaluate the efficacy of bentracimab (PB2452) in reversal of ticagrelor in subjects aged 50-80 years old. (2024). Accessed. March 24, 2026: https:\/\/clinicaltrials.gov\/study\/NCT04122170."},{"key":"ref16","unstructured":"ClinicalTrials.gov. Bentracimab in ticagrelor-treated patients with uncontrolled bleeding or requiring urgent surgery or invasive procedure (REVERSE-IT). (2024). Accessed. March 24, 2026: https:\/\/clinicaltrials.gov\/study\/NCT04286438."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/jocs.15636","article-title":"Ticagrelor use and practice patterns among Canadian cardiac surgeons","volume":"36","author":"Makhdoum A","year":"2021","unstructured":"Makhdoum A, Dhingra NK, Kirubaharan A, et al.. Ticagrelor use and practice patterns among Canadian cardiac surgeons. J Card Surg. 2021, 36:2793-801. 10.1111\/jocs.15636","journal-title":"J Card Surg"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2309300","article-title":"Reversal of platelet inhibition in patients receiving ticagrelor","volume":"23","author":"Adamski P","year":"2022","unstructured":"Adamski P, Skonieczny G, Hajdukiewicz T, Kern A, Kubica J. Reversal of platelet inhibition in patients receiving ticagrelor. Rev Cardiovasc Med. 2022, 23:300. 10.31083\/j.rcm2309300","journal-title":"Rev Cardiovasc Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.08.08","article-title":"Targeting ticagrelor: a novel therapy for emergency reversal","volume":"7","author":"Cave B","year":"2019","unstructured":"Cave B, Rawal A, Ardeshna D, Ibebuogu UN, Sai-Sudhakar CB, Khouzam RN. Targeting ticagrelor: a novel therapy for emergency reversal. Ann Transl Med. 2019, 7:410. 10.21037\/atm.2019.08.08","journal-title":"Ann Transl Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100047","article-title":"Bentracimab for ticagrelor reversal in patients undergoing urgent surgery","volume":"1","author":"Bhatt DL","year":"2022","unstructured":"Bhatt DL, Pollack CV, Mazer CD, et al.. Bentracimab for ticagrelor reversal in patients undergoing urgent surgery. NEJM Evid. 2022, 1:EVIDoa2100047. 10.1056\/EVIDoa2100047","journal-title":"NEJM Evid"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartjsupp\/suae033","article-title":"ANMCO\/SIMEU consensus document on the use of reversal agents for antithrombotic therapies in patients with ongoing bleeding or at high risk of haemorrhagic events","volume":"26","author":"De Luca L","year":"2024","unstructured":"De Luca L, Pugliese FR, Susi B, et al.. ANMCO\/SIMEU consensus document on the use of reversal agents for antithrombotic therapies in patients with ongoing bleeding or at high risk of haemorrhagic events. Eur Heart J Suppl. 2024, 26:ii211-20. 10.1093\/eurheartjsupp\/suae033","journal-title":"Eur Heart J Suppl"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1693738","article-title":"Antagonizing P2Y12 receptor inhibitors: current and future options","volume":"119","author":"Trenk D","year":"2019","unstructured":"Trenk D, Hille L, Leggewie S, et al.. Antagonizing P2Y12 receptor inhibitors: current and future options. Thromb Haemost. 2019, 119:1606-16. 10.1055\/s-0039-1693738","journal-title":"Thromb Haemost"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/10760296221110568","article-title":"Costs and healthcare resource utilization associated with idarucizumab or andexanet alfa oral anticoagulant reversal in patients hospitalized with life-threatening bleeds","volume":"28","author":"Spyropoulos AC","year":"2022","unstructured":"Spyropoulos AC, Hartaigh B\u00d3, Cao Z, Caberwal H, Lipkin C, Petrini M, Wang C. Costs and healthcare resource utilization associated with idarucizumab or andexanet alfa oral anticoagulant reversal in patients hospitalized with life-threatening bleeds. Clin Appl Thromb Hemost. 2022, 28:10760296221110568. 10.1177\/10760296221110568","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.10079","article-title":"Availability of specific direct oral anticoagulant reversal agents in US hospitals","volume":"4","author":"Kanjee Z","year":"2021","unstructured":"Kanjee Z, McCann ML, Freed JA. Availability of specific direct oral anticoagulant reversal agents in US hospitals. JAMA Netw Open. 2021, 4:e2110079. 10.1001\/jamanetworkopen.2021.10079","journal-title":"JAMA Netw Open"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1177\/10760296231176808","article-title":"Reversal of oral anticoagulants: a survey of contemporary practice trends (ReACT)","volume":"29","author":"Deng H","year":"2023","unstructured":"Deng H, Nutescu EA, DiDomenico RJ. Reversal of oral anticoagulants: a survey of contemporary practice trends (ReACT). Clin Appl Thromb Hemost. 2023, 29:10760296231176808. 10.1177\/10760296231176808","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp160520","article-title":"Factors associated with availability of anticoagulation reversal agents in rural and community emergency departments","volume":"75","author":"Faine BA","year":"2018","unstructured":"Faine BA, Amendola J, Homan J, Ahmed A, Mohr N. Factors associated with availability of anticoagulation reversal agents in rural and community emergency departments. Am J Health Syst Pharm. 2018, 75:72-7. 10.2146\/ajhp160520","journal-title":"Am J Health Syst Pharm"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Tomaselli GF","year":"2020","unstructured":"Tomaselli GF, Mahaffey KW, Cuker A, et al.. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020, 76:594-622. 10.1016\/j.jacc.2020.04.053","journal-title":"J Am Coll Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/480097-bentracimab-for-surgical-and-perioperative-bleeding-clinical-efficacy-emerging-safety-concerns-and-implementation-challenges-cost-accessibility-and-evidence-gaps","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T21:01:44Z","timestamp":1777842104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/480097-bentracimab-for-surgical-and-perioperative-bleeding-clinical-efficacy-emerging-safety-concerns-and-implementation-challenges-cost-accessibility-and-evidence-gaps"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,3]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.108189","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,3]]}}}